{"id":{"repo_id":"cornell","oai_identifier":"oai:ecommons.cornell.edu:1813/110433"},"canonical_url":"https://search.ndltd.org/etd/cornell/oai:ecommons.cornell.edu:1813/110433","repository":{"repo_id":"cornell","name":"Cornell University","base_url":"https://ecommons.cornell.edu/server/oai/request"},"display":{"title":"NANOMEDICINES FOR TREATMENT OF OTITIS MEDIA","abstract":"Otitis Media (OM) is the most common reason for U.S. children to get prescribed antibiotics. Current oral multidose antibiotics have the potential for causing a range of side effects and development of antimicrobial resistance (AMR) due to systemic antibiotic exposure. Developing innovative antimicrobials with single-dose delivery and sustained efficacy is an effective strategy to circumvent these negative impacts of oral antibiotics. To achieve this goal, we synthesized vanadium pentoxide nanowires (V2O5) which could turn metabolic products from pathogens into a potentantimicrobial, hypohalous acid. This system was applied to the OM treatment in a chinchilla model. Single-dose V2O5 formulation was given through chinchilla’s bullae and could completely eradicate OM from Streptococcus pneumoniae in the middle ear in 7 days. In addition, no tissue toxicity was observed at the given dose of V2O5 formulation. Nevertheless, due to the micrometer length of the V2O5 nanowires, the formulation had to be delivered via intratympanic or intrabullae injections. To further achieve non-invasive transtympanic delivery, we developed sub-10-nm silver nanoparticles, stabilized with polyvinylpyrrolidone (AgNPs-PVP), with the potential of penetrating intact tympanic membranes. AgNPs-PVP showed high antimicrobial efficacy against the two main OM pathogens, namely non-typeable Haemophilus influenzae and Streptococcus pneumoniae. To ensure sustained presence of AgNPs-PVP in the middle ear, a formulation based on poloxamer 407 (P407) was designed such that an AgNPs-containing solution can be administered through the tympanic membrane, which then gels quickly into a firm hydrogel, delivering prolonged antimicrobial effect. Future research will focus on surface functionalization of the AgNPs with chemical permeation enhancer to enable trans tympanic delivery of nanoparticles.","abstract_html":"Otitis Media (OM) is the most common reason for U.S. children to get prescribed antibiotics. Current oral multidose antibiotics have the potential for causing a range of side effects and development of antimicrobial resistance (AMR) due to systemic antibiotic exposure. Developing innovative antimicrobials with single-dose delivery and sustained efficacy is an effective strategy to circumvent these negative impacts of oral antibiotics. To achieve this goal, we synthesized vanadium pentoxide nanowires (V2O5) which could turn metabolic products from pathogens into a potentantimicrobial, hypohalous acid. This system was applied to the OM treatment in a chinchilla model. Single-dose V2O5 formulation was given through chinchilla’s bullae and could completely eradicate OM from Streptococcus pneumoniae in the middle ear in 7 days. In addition, no tissue toxicity was observed at the given dose of V2O5 formulation. Nevertheless, due to the micrometer length of the V2O5 nanowires, the formulation had to be delivered via intratympanic or intrabullae injections. To further achieve non-invasive transtympanic delivery, we developed sub-10-nm silver nanoparticles, stabilized with polyvinylpyrrolidone (AgNPs-PVP), with the potential of penetrating intact tympanic membranes. AgNPs-PVP showed high antimicrobial efficacy against the two main OM pathogens, namely non-typeable Haemophilus influenzae and Streptococcus pneumoniae. To ensure sustained presence of AgNPs-PVP in the middle ear, a formulation based on poloxamer 407 (P407) was designed such that an AgNPs-containing solution can be administered through the tympanic membrane, which then gels quickly into a firm hydrogel, delivering prolonged antimicrobial effect. Future research will focus on surface functionalization of the AgNPs with chemical permeation enhancer to enable trans tympanic delivery of nanoparticles.","abstract_has_math":false,"creators":["Ma, XIaojing"],"institution":"Cornell University","degree_name":"M.S., Chemical Engineering","degree_level":"Master of Science","degree_discipline":"Chemical Engineering","degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":["Yang, Rong"],"committee_members":["Daniel, Susan"],"year":2021,"date_issued":"2021-08","date_published":"2021-08","updated_at":"2026-11-19T03:08:55Z","subjects":[],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.doi","label":"DOI","values":["https://doi.org/10.7298/pv83-w979"],"render_values":[{"text":"https://doi.org/10.7298/pv83-w979","href":"https://doi.org/10.7298/pv83-w979","code":true}]},{"key":"dc:identifier.bibid","label":"Dc Identifier Bibid","values":["15160112"],"render_values":[{"text":"15160112","href":null,"code":true}]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["ProQuest Submission ID: 11232","ProQuest Publication ID: 28647646"],"render_values":[{"text":"ProQuest Submission ID: 11232","href":null,"code":true},{"text":"ProQuest Publication ID: 28647646","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/1813/110433","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/1813/110433","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://ecommons.cornell.edu/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aecommons.cornell.edu%3A1813%2F110433","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.chair","label":"Chair","values":["Yang, Rong"]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Daniel, Susan"]},{"key":"dc:creator","label":"Author","values":["Ma, XIaojing"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2021-12-20T20:34:32Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2022-09-10T06:00:17Z"]},{"key":"dc:date.issued","label":"Date","values":["2021-08"]},{"key":"dc:relation.uri","label":"Dc Relation URI","values":["https://newcatalog.library.cornell.edu/catalog/15160112"]},{"key":"dc:type","label":"Dc Type","values":["dissertation or thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemical Engineering"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Master of Science"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.S., Chemical Engineering"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Cornell University"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.bibid","label":"Dc Identifier Bibid","values":["15160112"]},{"key":"dc:identifier.doi","label":"DOI","values":["https://doi.org/10.7298/pv83-w979"]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["ProQuest Submission ID: 11232","ProQuest Publication ID: 28647646"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/1813/110433"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"cerif:openaire","label":"Cerif Openaire","values":["<Publication xmlns=\"https://www.openaire.eu/cerif-profile/1.1/\" id=\"c6053bb9-0ebb-49eb-935e-66c58a25a8a2\"> <Type xmlns=\"https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types\">http://purl.org/coar/resource_type/c_1843</Type> <Language>en</Language> <Title>NANOMEDICINES FOR TREATMENT OF OTITIS MEDIA</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2021-08</PublicationDate> <DOI>https://doi.org/10.7298/pv83-w979</DOI> <Authors> <Author> <DisplayName>Ma, XIaojing</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <OrgUnit /> </Publisher> </Publishers> <Abstract>Otitis Media (OM) is the most common reason for U.S. children to get prescribed antibiotics. Current oral multidose antibiotics have the potential for causing a range of side effects and development of antimicrobial resistance (AMR) due to systemic antibiotic exposure. Developing innovative antimicrobials with single-dose delivery and sustained efficacy is an effective strategy to circumvent these negative impacts of oral antibiotics. To achieve this goal, we synthesized vanadium pentoxide nanowires (V2O5) which could turn metabolic products from pathogens into a potentantimicrobial, hypohalous acid. This system was applied to the OM treatment in a chinchilla model. Single-dose V2O5 formulation was given through chinchilla’s bullae and could completely eradicate OM from Streptococcus pneumoniae in the middle ear in 7 days. In addition, no tissue toxicity was observed at the given dose of V2O5 formulation. Nevertheless, due to the micrometer length of the V2O5 nanowires, the formulation had to be delivered via intratympanic or intrabullae injections. To further achieve non-invasive transtympanic delivery, we developed sub-10-nm silver nanoparticles, stabilized with polyvinylpyrrolidone (AgNPs-PVP), with the potential of penetrating intact tympanic membranes. AgNPs-PVP showed high antimicrobial efficacy against the two main OM pathogens, namely non-typeable Haemophilus influenzae and Streptococcus pneumoniae. To ensure sustained presence of AgNPs-PVP in the middle ear, a formulation based on poloxamer 407 (P407) was designed such that an AgNPs-containing solution can be administered through the tympanic membrane, which then gels quickly into a firm hydrogel, delivering prolonged antimicrobial effect. Future research will focus on surface functionalization of the AgNPs with chemical permeation enhancer to enable trans tympanic delivery of nanoparticles.</Abstract> <Access xmlns=\"http://purl.org/coar/access_right\" > </Access> </Publication>"]},{"key":"cris:virtual.author","label":"Cris Virtual Author","values":["Ma, XIaojing"]},{"key":"cris:virtualsource.collection","label":"Cris Virtualsource Collection","values":["5893a6ea-7af3-41d7-abc6-04bcd26ab5df"]},{"key":"dc:description","label":"Description","values":["68 pages"]},{"key":"dc:description.abstract","label":"Abstract","values":["Otitis Media (OM) is the most common reason for U.S. children to get prescribed antibiotics. Current oral multidose antibiotics have the potential for causing a range of side effects and development of antimicrobial resistance (AMR) due to systemic antibiotic exposure. Developing innovative antimicrobials with single-dose delivery and sustained efficacy is an effective strategy to circumvent these negative impacts of oral antibiotics. To achieve this goal, we synthesized vanadium pentoxide nanowires (V2O5) which could turn metabolic products from pathogens into a potentantimicrobial, hypohalous acid. This system was applied to the OM treatment in a chinchilla model. Single-dose V2O5 formulation was given through chinchilla’s bullae and could completely eradicate OM from Streptococcus pneumoniae in the middle ear in 7 days. In addition, no tissue toxicity was observed at the given dose of V2O5 formulation. Nevertheless, due to the micrometer length of the V2O5 nanowires, the formulation had to be delivered via intratympanic or intrabullae injections. To further achieve non-invasive transtympanic delivery, we developed sub-10-nm silver nanoparticles, stabilized with polyvinylpyrrolidone (AgNPs-PVP), with the potential of penetrating intact tympanic membranes. AgNPs-PVP showed high antimicrobial efficacy against the two main OM pathogens, namely non-typeable Haemophilus influenzae and Streptococcus pneumoniae. To ensure sustained presence of AgNPs-PVP in the middle ear, a formulation based on poloxamer 407 (P407) was designed such that an AgNPs-containing solution can be administered through the tympanic membrane, which then gels quickly into a firm hydrogel, delivering prolonged antimicrobial effect. Future research will focus on surface functionalization of the AgNPs with chemical permeation enhancer to enable trans tympanic delivery of nanoparticles."]},{"key":"dc:description.collection","label":"Dc Description Collection","values":["Cornell Theses and Dissertations"]},{"key":"dc:format.mimetype","label":"Dc Format Mimetype","values":["application/pdf"]},{"key":"dcterms:license","label":"Dcterms License","values":["https://hdl.handle.net/1813/59810"]},{"key":"dc:title","label":"Title","values":["NANOMEDICINES FOR TREATMENT OF OTITIS MEDIA"]},{"key":"dspace:entity.type","label":"Dspace Entity Type","values":["Publication"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"cerif:openaire":["<Publication xmlns=\"https://www.openaire.eu/cerif-profile/1.1/\" id=\"c6053bb9-0ebb-49eb-935e-66c58a25a8a2\"> <Type xmlns=\"https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types\">http://purl.org/coar/resource_type/c_1843</Type> <Language>en</Language> <Title>NANOMEDICINES FOR TREATMENT OF OTITIS MEDIA</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2021-08</PublicationDate> <DOI>https://doi.org/10.7298/pv83-w979</DOI> <Authors> <Author> <DisplayName>Ma, XIaojing</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <OrgUnit /> </Publisher> </Publishers> <Abstract>Otitis Media (OM) is the most common reason for U.S. children to get prescribed antibiotics. Current oral multidose antibiotics have the potential for causing a range of side effects and development of antimicrobial resistance (AMR) due to systemic antibiotic exposure. Developing innovative antimicrobials with single-dose delivery and sustained efficacy is an effective strategy to circumvent these negative impacts of oral antibiotics. To achieve this goal, we synthesized vanadium pentoxide nanowires (V2O5) which could turn metabolic products from pathogens into a potentantimicrobial, hypohalous acid. This system was applied to the OM treatment in a chinchilla model. Single-dose V2O5 formulation was given through chinchilla’s bullae and could completely eradicate OM from Streptococcus pneumoniae in the middle ear in 7 days. In addition, no tissue toxicity was observed at the given dose of V2O5 formulation. Nevertheless, due to the micrometer length of the V2O5 nanowires, the formulation had to be delivered via intratympanic or intrabullae injections. To further achieve non-invasive transtympanic delivery, we developed sub-10-nm silver nanoparticles, stabilized with polyvinylpyrrolidone (AgNPs-PVP), with the potential of penetrating intact tympanic membranes. AgNPs-PVP showed high antimicrobial efficacy against the two main OM pathogens, namely non-typeable Haemophilus influenzae and Streptococcus pneumoniae. To ensure sustained presence of AgNPs-PVP in the middle ear, a formulation based on poloxamer 407 (P407) was designed such that an AgNPs-containing solution can be administered through the tympanic membrane, which then gels quickly into a firm hydrogel, delivering prolonged antimicrobial effect. Future research will focus on surface functionalization of the AgNPs with chemical permeation enhancer to enable trans tympanic delivery of nanoparticles.</Abstract> <Access xmlns=\"http://purl.org/coar/access_right\" > </Access> </Publication>"],"cris:virtual.author":["Ma, XIaojing"],"cris:virtualsource.collection":["5893a6ea-7af3-41d7-abc6-04bcd26ab5df"],"dc:contributor.chair":["Yang, Rong"],"dc:contributor.committeemember":["Daniel, Susan"],"dc:creator":["Ma, XIaojing"],"dc:date.accessioned":["2021-12-20T20:34:32Z"],"dc:date.available":["2022-09-10T06:00:17Z"],"dc:date.issued":["2021-08"],"dc:description":["68 pages"],"dc:description.abstract":["Otitis Media (OM) is the most common reason for U.S. children to get prescribed antibiotics. Current oral multidose antibiotics have the potential for causing a range of side effects and development of antimicrobial resistance (AMR) due to systemic antibiotic exposure. Developing innovative antimicrobials with single-dose delivery and sustained efficacy is an effective strategy to circumvent these negative impacts of oral antibiotics. To achieve this goal, we synthesized vanadium pentoxide nanowires (V2O5) which could turn metabolic products from pathogens into a potentantimicrobial, hypohalous acid. This system was applied to the OM treatment in a chinchilla model. Single-dose V2O5 formulation was given through chinchilla’s bullae and could completely eradicate OM from Streptococcus pneumoniae in the middle ear in 7 days. In addition, no tissue toxicity was observed at the given dose of V2O5 formulation. Nevertheless, due to the micrometer length of the V2O5 nanowires, the formulation had to be delivered via intratympanic or intrabullae injections. To further achieve non-invasive transtympanic delivery, we developed sub-10-nm silver nanoparticles, stabilized with polyvinylpyrrolidone (AgNPs-PVP), with the potential of penetrating intact tympanic membranes. AgNPs-PVP showed high antimicrobial efficacy against the two main OM pathogens, namely non-typeable Haemophilus influenzae and Streptococcus pneumoniae. To ensure sustained presence of AgNPs-PVP in the middle ear, a formulation based on poloxamer 407 (P407) was designed such that an AgNPs-containing solution can be administered through the tympanic membrane, which then gels quickly into a firm hydrogel, delivering prolonged antimicrobial effect. Future research will focus on surface functionalization of the AgNPs with chemical permeation enhancer to enable trans tympanic delivery of nanoparticles."],"dc:description.collection":["Cornell Theses and Dissertations"],"dc:format.mimetype":["application/pdf"],"dc:identifier.bibid":["15160112"],"dc:identifier.doi":["https://doi.org/10.7298/pv83-w979"],"dc:identifier.other":["ProQuest Submission ID: 11232","ProQuest Publication ID: 28647646"],"dc:identifier.uri":["https://hdl.handle.net/1813/110433"],"dc:language.iso":["en"],"dc:relation.uri":["https://newcatalog.library.cornell.edu/catalog/15160112"],"dcterms:license":["https://hdl.handle.net/1813/59810"],"dc:title":["NANOMEDICINES FOR TREATMENT OF OTITIS MEDIA"],"dc:type":["dissertation or thesis"],"dspace:entity.type":["Publication"],"others:access_status":["open.access"],"thesis:degree_discipline":["Chemical Engineering"],"thesis:degree_level":["Master of Science"],"thesis:degree_name":["M.S., Chemical Engineering"],"thesis:institution_name":["Cornell University"]},"updated_at":"2026-11-19T03:08:55Z"}